

S6 Table. LS burden reduction after vaccination with CSP combination antigens.

| Combination with <i>Pb</i> CSP | | | Combination with <i>Py</i> CSP | | |
|---------------------------------------|--------------------|--------------------|---------------------------------------|--------------------|-------------------------|
| Antigen | % Reduction | P-value (N) | Antigen | % Reduction | P-value |
| LISP1-1 ^a | 79.08 | 0.047 (5) | SLARP-4 ^b | 57.58 | 0.009 (10) |
| SLARP-4 ^a | 76.07 | 0.047 (5) | PF3D7_0506200 ^b | 57.41 | 0.093 (10) [#] |
| PF3D7_1456100 ^a | 55.03 | 0.047 (5) | LISP1-3 ^b | 55.63 | 0.032 (10) |
| 2 x CSP^a | 53.48 | 0.081 (10) | PF3D7_1207400 ^b | 49.10 | 0.081 (10) [#] |
| | | | PF3D7_1411500 ^b | 40.85 | 0.061 (10) [#] |
| | | | 2 x CSP^b | 39.96 | 0.154 (10) |
| | | | PF3D7_1241500 ^b | 27.42 | 0.061 (10) [#] |

Median percent reduction in LS burden per tested combination vaccine of CSP and the indicated antigen, as compared to combined CSP and empty vector. Antigens are listed from greatest to smallest percent reduction. Only antigens that significantly (# or nearly significantly) reduced LS burden are shown. Double dose (2x) CSP is shown in bold. Doubling the CSP dose did not significantly reduce LS parasite burden beyond that achieved with CSP in combination with empty vector.

^aGG immunization; ^bEP immunization; ^cIM immunization. (N), Number of mice used for immunization